nanoPET Pharma GmbH
As a technology and service provider to the biopharmaceutical industry nanoPET focuses on the R&D, production as well as marketing of innovative drug substances for diagnostic imaging. Nanotechnology is a key element of our business and allows us to offer you materials with unique properties. In June 2010 we launched the first comprehensive portfolio of pre‐clincal small animal contrast agents. Twenty‐one products for the main imaging modalities MRI, CT, ultrasound and optical imaging are available to the imaging community worldwide. nanoPET offers the experience of its experts to provide services to biopharmaceutical companies and imaging equipment manufacturers (Consulting & Service). First transactions with major companies highlight the potential for nanotechnology in preclinical research.
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Pharmaceuticals
- Market Focus:
- Globally (various continents)
This company also provides solutions for other industrial applications.
Please, visit the following links for more info:
About Us
nanoPET Tracers
Finally, our core technology “Positron-emitting inorganic nanoparticles for molecular- and cell-specific positron emission tomography (PET)” will be developed for human clinical imaging. It represents a whole new class of PET Tracers with a market potential in the hundred millions.
Where we are
nanoPET's 1000m² research and production site is located in Berlin, Germany, in close vicinity to the Charité (Campus Mitte) – one of Europe’s leading university hospitals.